Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Non-Current Liabilities (2016 - 2025)

United Therapeutics (UTHR) has disclosed Total Non-Current Liabilities for 17 consecutive years, with $560.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 24.05% to $560.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $560.6 million through Dec 2025, down 24.05% year-over-year, with the annual reading at $560.6 million for FY2025, 24.05% down from the prior year.
  • Total Non-Current Liabilities hit $560.6 million in Q4 2025 for United Therapeutics, up from $546.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q3 2023 to a low of $527.1 million in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $976.3 million across 5 years, with a median of $1.1 billion in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: grew 11.49% in 2023 and later plummeted 43.46% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $1.1 billion in 2021, then rose by 3.42% to $1.1 billion in 2022, then fell by 3.39% to $1.1 billion in 2023, then plummeted by 33.17% to $738.1 million in 2024, then decreased by 24.05% to $560.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for UTHR at $560.6 million in Q4 2025, $546.3 million in Q3 2025, and $527.1 million in Q2 2025.